The studies on the role of CGRP and CGRP-related therapy in obese and diabetic animals were translated into two randomized, double-blind, placebo-controlled trials to assess the safety and metabolic effects of eptinezumab, an anti-CGRP antibody, in non-migraine overweight/obese patients and patients with T1DM [95]. The gene discussed is CALCA; the disease is migraine disorder.